or Try an Advanced Search...

    Technical Analysis for SPRY - ARS Pharmaceuticals, Inc.

    Grade Last Price % Change Price Change
    D 14.40 0.21% 0.03
    SPRY closed up 4.81 percent on Tuesday, November 26, 2024, on 60 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Down Up
    Historical SPRY trend table...
    Date Alert Name Type % Chg
    Wide Bands Range Expansion 0.21%
    Oversold Stochastic Weakness 0.21%
    180 Bearish Setup Bearish Swing Setup 5.03%
    Wide Bands Range Expansion 5.03%
    Oversold Stochastic Weakness 5.03%
    Slingshot Bearish Bearish Swing Setup 2.86%
    Bullish Engulfing Bullish 2.86%
    Stochastic Buy Signal Bullish 2.86%
    Wide Bands Range Expansion 2.86%
    Oversold Stochastic Weakness 2.86%
    Older End-of-Day Signals for SPRY ...

       Recent Intraday Alerts

    Alert Time
    Up 1% 9 minutes ago
    60 Minute Opening Range Breakout 21 minutes ago
    Rose Above Previous Day's High 21 minutes ago
    Down 1% about 1 hour ago
    Possible NR7 about 21 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    SPRY Chart by TradingView
    Basic chart:

    Profile

    ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Allergy Respiratory Therapy Respiratory Diseases Type I Hypersensitivity Allergology Nasal Administration Anaphylaxis

    Is SPRY a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 20 ARS Pharmaceuticals: Demand Curve Is Key Unknown
    Nov 15 Loss-Making ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Expected To Breakeven In The Medium-Term
    Nov 14 ARS Pharmaceuticals Inc (SPRY) Q3 2024 Earnings Call Highlights: Strong Cash Position and NEPHI ...
    Nov 13 ARS Pharmaceuticals, Inc. (SPRY) Q3 2024 Earnings Call Transcript
    Nov 13 ARS Pharmaceuticals, Inc. (SPRY) Reports Q3 Loss, Misses Revenue Estimates
    Nov 13 ARS Pharmaceuticals GAAP EPS of -$0.20 misses by $0.05, revenue of $2.07M
    Nov 13 ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates
    Nov 13 Earnings Scheduled For November 13, 2024
    Nov 12 ARS Pharmaceuticals announces agreement with ALK to commercialize neffy
    Nov 11 ALK snags EU and Canada rights to anaphylaxis nasal spray Neffy for $145m
    See more SPRY news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 18.51
    52 Week Low 4.77
    Average Volume 1,097,890
    200-Day Moving Average 11.03
    50-Day Moving Average 14.82
    20-Day Moving Average 14.83
    10-Day Moving Average 13.88
    Average True Range 1.02
    RSI (14) 47.92
    ADX 14.45
    +DI 21.73
    -DI 23.45
    Chandelier Exit (Long, 3 ATRs) 15.46
    Chandelier Exit (Short, 3 ATRs) 16.06
    Upper Bollinger Bands 17.21
    Lower Bollinger Band 12.45
    Percent B (%b) 0.4
    BandWidth 32.12
    MACD Line -0.32
    MACD Signal Line -0.16
    MACD Histogram -0.1644
    Fundamentals Value
    Market Cap 1.38 Billion
    Num Shares 96 Million
    EPS -0.64
    Price-to-Earnings (P/E) Ratio -22.45
    Price-to-Sales 22655.34
    Price-to-Book 2.63
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 15.62
    Resistance 3 (R3) 15.50 14.98 15.41
    Resistance 2 (R2) 14.98 14.66 15.03 15.34
    Resistance 1 (R1) 14.67 14.46 14.83 14.79 15.27
    Pivot Point 14.15 14.15 14.22 14.20 14.15
    Support 1 (S1) 13.84 13.83 14.00 13.96 13.47
    Support 2 (S2) 13.32 13.63 13.37 13.40
    Support 3 (S3) 13.01 13.32 13.33
    Support 4 (S4) 13.13